Bevicra Injection
Marketer
Glenmark Pharmaceuticals Ltd
Salt Composition
Bevacizumab (100mg/4ml)
Overview Bevicra Injection
Bevicra Injection combats various cancers, including colorectal, non-small cell lung, kidney, brain, ovarian, and cervical cancers. Its mechanism involves inhibiting tumor angiogenesis, thus hindering tumor growth. Highly effective, it's often a first-line treatment when combined with other anticancer therapies. Administered intravenously via infusion or port, dosage and treatment duration are individually determined by your physician, who will also monitor for infusion reactions like hypertension and respiratory distress. Continued use depends on disease control and manageable side effects, a decision made in consultation with your doctor. Regular blood pressure monitoring and urine protein level checks may be recommended. Common side effects include rectal hemorrhage, altered taste perception, and cephalalgia. Pre-surgical notification is crucial due to Bevicra's potential to impair wound healing and increase bleeding risk; any unusual bleeding warrants immediate medical attention. Disclose pregnancy, pregnancy plans, or breastfeeding to your physician. Comprehensive medication disclosure to your healthcare provider is vital due to potential drug interactions.
Uses of Bevicra Injection
Colorectal cancer, ovarian neoplasm, cervical malignancy, renal cell carcinoma, intracranial tumor, and non-small cell lung carcinoma.
Major Benefits of Bevicra Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Bevicra Injection:
- Exfoliative dermatitis
- High blood pressure
- Nosebleeds
- Protein in urine
- Decreased appetite
- Electrolyte imbalance
- Peripheral sensory neuropathy
- Breathlessness
- Thromboembolism
- Wound healing complications
- Ovarian failure
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Mucosal inflammation
- Abscess
- Cellulitis
- Hypersensitivity
- Rectovaginal fistula
How to use Bevicra Injection:
This medication will be administered by your healthcare provider; self-medication is strictly prohibited.
How Bevicra Injection works:
Bevicra Injection is an anti-angiogenesis therapy. Its mechanism of action involves inhibiting vascular endothelial growth factor (VEGF), a protein crucial for blood vessel formation. This action deprives cancerous tumors of the oxygen and nutrients supplied by newly formed blood vessels.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Bevicra Injection may pose unknown risks. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Using Bevicra Injection during pregnancy may pose risks. While human research is scant, animal studies indicate potential harm to a developing fetus. A physician will assess the advantages against possible risks prior to prescribing. Physician consultation is advised.
Breast feedingCONSULT YOUR DOCTOR
Use of Bevicra Injection while breastfeeding is likely unsafe. Available human data indicate potential transfer to breast milk, posing a risk to the infant.
DrivingUNSAFE
Administering Bevicra Injection may induce adverse reactions that could compromise driving capabilities. Drowsiness and loss of consciousness have been observed in patients receiving Bevicra Injection, potentially hindering safe operation of a vehicle.
KidneySAFE IF PRESCRIBED
The use of Bevicra Injection in patients with kidney impairment appears to pose minimal risk. Existing evidence indicates dose modification may be unnecessary, but physician consultation is recommended.
LiverSAFE IF PRESCRIBED
The use of Bevicra Injection in patients with liver disease appears to present a low risk. Current evidence indicates dose modification may be unnecessary for this population. Physician consultation is recommended.
What if you forget to take Bevicra Injection :
Omit Bevicra Injection doses necessitate physician consultation.
Facts to Know About Bevicra Injection
| Label | Value |
|---|---|
| Chemical Type | Monoclonal antibody |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
| Actions | VEGF inhibitor |
3,018 People bought this recently